Erythropoietin-induced, antibody-mediated pure red cell aplasia

Jérôme Rossert; Brad Maroni; Pedro Aljama; Nicole Casadevall; Max Cooper; Robert Delage; Kai Uwe Eckardt; Angel Martin Luis De Francisco; Walter Hörl; Wolfgang Jelkmann; David Johnson; Francesco Locatelli; Iain Macdougall; Allen R. Nissenson; Carol Pollock; Huub Schellekens; Robin Thorpe; Edwin Toffelmire

Erythropoietin-induced, antibody-mediated pure red cell aplasia

Jérôme Rossert^*, Brad Maroni, Pedro Aljama, Nicole Casadevall, Max Cooper, Robert Delage, Kai Uwe Eckardt, Angel Martin Luis De Francisco, Walter Hörl, Wolfgang Jelkmann, David Johnson, Francesco Locatelli, Iain Macdougall, Allen R. Nissenson, Carol Pollock, Huub Schellekens, Robin Thorpe, Edwin Toffelmire

^*Corresponding author for this work

Institute of Physiology

22 Citations (Scopus)

Abstract

Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.

Original language	English
Journal	European Journal of Clinical Investigation, Supplement
Volume	35
Issue number	3
Pages (from-to)	95-99
Number of pages	5
ISSN	0960-135X
Publication status	Published - 12.2005

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Rossert, J., Maroni, B., Aljama, P., Casadevall, N., Cooper, M., Delage, R., Eckardt, K. U., De Francisco, A. M. L., Hörl, W., Jelkmann, W., Johnson, D., Locatelli, F., Macdougall, I., Nissenson, A. R., Pollock, C., Schellekens, H., Thorpe, R., & Toffelmire, E. (2005). Erythropoietin-induced, antibody-mediated pure red cell aplasia. European Journal of Clinical Investigation, Supplement, 35(3), 95-99.

@article{c75a44f5c22f49f8988e113f1251947a,

title = "Erythropoietin-induced, antibody-mediated pure red cell aplasia",

abstract = "Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.",

author = "J{\'e}r{\^o}me Rossert and Brad Maroni and Pedro Aljama and Nicole Casadevall and Max Cooper and Robert Delage and Eckardt, {Kai Uwe} and {De Francisco}, {Angel Martin Luis} and Walter H{\"o}rl and Wolfgang Jelkmann and David Johnson and Francesco Locatelli and Iain Macdougall and Nissenson, {Allen R.} and Carol Pollock and Huub Schellekens and Robin Thorpe and Edwin Toffelmire",

year = "2005",

month = dec,

language = "English",

volume = "35",

pages = "95--99",

journal = "European Journal of Clinical Investigation, Supplement",

issn = "0960-135X",

number = "3",

}

Rossert, J, Maroni, B, Aljama, P, Casadevall, N, Cooper, M, Delage, R, Eckardt, KU, De Francisco, AML, Hörl, W, Jelkmann, W, Johnson, D, Locatelli, F, Macdougall, I, Nissenson, AR, Pollock, C, Schellekens, H, Thorpe, R & Toffelmire, E 2005, 'Erythropoietin-induced, antibody-mediated pure red cell aplasia', European Journal of Clinical Investigation, Supplement, vol. 35, no. 3, pp. 95-99.

TY - JOUR

T1 - Erythropoietin-induced, antibody-mediated pure red cell aplasia

AU - Rossert, Jérôme

AU - Maroni, Brad

AU - Aljama, Pedro

AU - Casadevall, Nicole

AU - Cooper, Max

AU - Delage, Robert

AU - Eckardt, Kai Uwe

AU - De Francisco, Angel Martin Luis

AU - Hörl, Walter

AU - Jelkmann, Wolfgang

AU - Johnson, David

AU - Locatelli, Francesco

AU - Macdougall, Iain

AU - Nissenson, Allen R.

AU - Pollock, Carol

AU - Schellekens, Huub

AU - Thorpe, Robin

AU - Toffelmire, Edwin

PY - 2005/12

Y1 - 2005/12

N2 - Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.

AB - Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients.

UR - http://www.scopus.com/inward/record.url?scp=28944443558&partnerID=8YFLogxK

M3 - Scientific review articles

C2 - 16281965

AN - SCOPUS:28944443558

SN - 0960-135X

VL - 35

SP - 95

EP - 99

JO - European Journal of Clinical Investigation, Supplement

JF - European Journal of Clinical Investigation, Supplement

IS - 3

ER -

Erythropoietin-induced, antibody-mediated pure red cell aplasia

Abstract

Research Areas and Centers

UN SDGs

Other files and links

Fingerprint

Cite this